Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

NCT02603120 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

567

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: ABC/DTG/3TC
DRUG: B/F/TAF
DRUG: ABC/DTG/3TC Placebo
DRUG: B/F/TAF Placebo

Sponsor

Gilead Sciences